| abstract |
The disclosure provides CD40-binding molecules comprising engineered human IgG domains, for example, human IgG1, IgG2, and IgG4 variants having mutations in the hinge domain, which exhibit altered binding activity to one or more Fey receptors. Also described herein are methods for selectively activating or inhibiting immune responses in a subject using the CD40-binding molecules. |